Breast Cancer

Treatment in Breast Cancer Influenced by Race and Socioeconomic Status

September 26, 2020

Race, socioeconomic status, and care barriers are factors that affect the timing of treatment and treatment duration throughout the care continuum according to a recent study.

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

September 25, 2020

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Palbociclib/Fulvestrant Prolongs PFS in Endocrine-Sensitive, HR+/HER2– Metastatic Breast Cancer

September 21, 2020

Patients with endocrine-sensitive hormone receptor–positive, HER2-negative metastatic breast cancer, treated with Frontline fulvestrant in combination with palbociclib experienced improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone, achieving the primary end point of the phase 2 FLIPPER trial.

In High-Risk Early Breast Cancer, Risk of Recurrence Is Reduced With Abemaciclib

September 20, 2020

Findings from the phase 3 monarchE trial reported at the ESMO Virtual Congress 2020 showed that the risk of invasive disease with ​abemaciclib plus endocrine therapy was significantly reduced versus endocrine therapy alone in patients with high-risk early hormone receptor-positive, HER2-negative breast cancer.

Responses Significantly Improved With Atezolizumab Regimen in Triple-Negative Breast Cancer

September 20, 2020

The pathologic complete responses were significantly improved with neoadjuvant atezolizumab in combination with nab-paclitaxel plus doxorubicin and cyclophosphamide compared with placebo and chemotherapyin patients with stage 2 or stage 3 triple-negative breast cancer.

Significant Benefit Observed in HR+/HER2- Breast Cancer With Dose-Dense iddEPC

September 20, 2020

Patients with HR-positive, HER2-negative breast cancer experienced significant benefit when treated with neoadjuvant chemotherapy with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide.

Abemaciclib Doublet Demonstrates OS Benefit in HR+, HER2- Metastatic Breast Cancer

September 20, 2020

Abemaciclib in combination with tamoxifen led to an improvement in overall survival compared with abemaciclib alone in patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Notably, the benefit of the combination was observed across all subgroups in the study, according to findings from the final OS analysis of the nextMONARCH trial presented during the 2020 European Society of Medical Oncology Virtual Congress.

Alpelisib and Fulvestrant Show Benefit for Breast Cancer Subgroups in SOLAR-1

September 19, 2020

Postmenopausal patients with PIK3CA-mutant, hormone receptor–positive, HER2-negative advanced breast cancer in the SOLAR-1 trial experienced prolonged overall survival with alpelisib and fulvestrant even though the study did not cross the prespecified O’Brien-Fleming efficacy boundary (P ≤ .0161), according to research presented at the 2020 ESMO Virtual Congress.

NeoTRIPaPDL1 Trial Showed TIL Activity With Guidance From PD-L1 Status

September 19, 2020

The combination of atezolizumab, carboplatin, and nab-paclitaxel increased pathological complete response by 10% or more in “immune-rich” patients with high-risk and locally advanced triple-negative breast cancer, as well as turned PD-L1 negative tumors positive most patients treated with immunotherapy, according to the phase 3 NeoTRIPaPDL1 trial data presented at the 2020 ESMO Virtual Congress.

Ipatasertib Combination Misses End Points in HR+ HER2- Advanced Breast Cancer

September 19, 2020

An improvement in progression-free survival and objective response rate was not observed with the addition of ipatasertib to paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive, HER2-negative advanced breast cancer.